Acurx Pharmaceuticals Inc... (ACXP)
NASDAQ: ACXP
· Real-Time Price · USD
5.11
0.25 (5.14%)
At close: Aug 15, 2025, 3:59 PM
5.12
0.20%
After-hours: Aug 15, 2025, 05:58 PM EDT
Acurx Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -4.4B | -11.88M | -14.1M | -16.44M | -16.73M | -16.05M | -14.58M | -12.72M | -13.15M | -12.33M | -12.09M | -11.46M | -12.56M | -13.94M | -12.75M | -11.21M | -7.89M | -4.79M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 658.67M | 2.32M | 3.07M | 3.76M | 4.28M | 4.07M | 3.77M | 3.24M | 3.23M | 3.14M | 3.19M | 3.07M | 5.65M | 7.19M | 6.56M | 6.27M | 3.18M | 1.09M |
Other Working Capital | -273.13K | -304.75K | 78.03K | -403.95K | -371.89K | 721.82K | -11.56M | -11.52M | -10.96M | -11.74M | 211.28M | 211.53M | 209.6M | 210.8M | -246.69K | -377.96K | 1.26M | -368.22K |
Other Non-Cash Items | 3.73B | 648.21K | 648.07K | 697.27K | 460.42K | 1.15M | 2.05M | 2.86M | 3.37M | 2.26M | 1.15M | 648.38K | -13.76K | 78.89K | 1.21M | 784.35K | 1.11M | 1.18M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -83.19K | -460.81K | n/a | -352.83K | -242.73K | -94.44K | -138.62K | 1.12M | 968.77K | 924.46K | 698.81K | 113.1K | -1.11M | 302.75K | 140.75K | -266.52K | 1.13M | -500.24K |
Operating Cash Flow | -8.16M | -9.37M | -10.38M | -12.33M | -12.23M | -10.93M | -9.8M | -7.1M | -7.19M | -7.6M | -7.54M | -7.55M | -8M | -6.34M | -5.01M | -4.47M | -2.6M | -3M |
Capital Expenditures | 4.00 | n/a | -5 | -5 | -5 | -5 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 66.5K |
Common Stock Repurchased | 610.26M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -802 | -802 | 210.53K | 2.43M | 5.97M | 5.97M | 5.76M | -151.11K | 86.00 | 13.00 | 13.00 | 14.79B | 14.78B | 14.78B | 14.78B | n/a | n/a | 1.12M |
Financial Cash Flow | 7.87M | 5.09M | 6.62M | 11.04M | 9.45M | 12.67M | 8.16M | 3.54M | 7.24M | 3.69M | 3.69M | 14.79B | 14.78B | 14.8B | 14.8B | 15.53M | 17.72M | 4.04M |
Net Cash Flow | -296.58K | -4.28M | -3.77M | -1.29M | -2.79M | 1.74M | -1.64M | -3.56M | 53K | -3.9M | -3.85M | -3.85M | -8M | 8.45M | 9.78M | 11.05M | 15.12M | 1.04M |
Free Cash Flow | -3.73B | -9.37M | -10.38M | -12.33M | -12.23M | -10.93M | -9.8M | -7.1M | -7.19M | -7.6M | -7.54M | -7.55M | -8M | -6.34M | -5.01M | -4.47M | -2.6M | -3M |